Overview

Preoperative levosimendán and Hip Fracture

Status:
Completed
Trial end date:
2019-04-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to evaluate whether preoperative optimization with levosimendan in heart failure patients undergoing hip fracture surgery improves haemodynamic and tissue perfusion parameters.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Hospital Universitario de Canarias
Collaborator:
Orion Corporation, Orion Pharma
Treatments:
Simendan
Criteria
Inclusion Criteria:

1. Patients due to undergo urgent of hip fracture.

2. Patients with cardiac failure (EF < 45 %).

3. Decompensated heart failure.

4. Informed consent provided by the patient.

Exclusion Criteria:

1. <18 years old

2. Emergency surgery

3. Serious aortic stenosis (< 1 cm2)

4. Sustained ventricular tachycardia or atrial fibrillation >140

5. Earlier episodes of "torsades depointes"

6. Systolic blood pressure < 85 mmHg

7. Serious kidney failure (GFR < 30 ml/min)

8. Serious liver failure (known class C Child-Pugh score)

9. Allergy levosimendan